On Wednesday, September 16, 2026, the webinar “Genitourinary Cancers: Between Clinical Practice and Innovation” will be held, focusing on the latest developments in the management of genitourinary tract cancers.
In recent years, the treatment of urological cancers has continued to grow in complexity and potential, making it necessary to stay constantly up to date on the latest scientific developments.
In the management of prostate cancer, there is growing debate over what the correct selection criteria are to ensure patients have the best treatment outcomes while minimizing the risks of overtreatment and avoidable toxicity. These variables are highly diverse, ranging from the simple extrapolation of inclusion criteria from clinical trials to more advanced concepts in molecular biology. Understanding the state-of-the-art in patient selection is essential for preparing to meet the challenges that the introduction of new therapies into clinical practice inevitably brings.
In the field of renal cell carcinoma, the latest year’s results from clinical research highlight the need to identify more effective and better-defined treatment alternatives following the failure of immunotherapy—a treatment that has become indispensable both in the adjuvant setting and as part of combination therapy for metastatic disease. In fact, this is a clinical area where, for a long time, no valid scientific data were available to answer the following questions: Does it make sense to re-administer immune checkpoint inhibitors after initial disease progression? What are the best alternatives in subsequent treatment lines?
Finally, the management of urothelial carcinomas, especially bladder cancer, is undergoing the most significant revolution among all genitourinary tract cancers.
The high rate of pathological complete responses with modern neoadjuvant treatments and the hope for refined monitoring of residual disease through the measurement of plasma and urinary tumor DNA offer reason to believe that non-operative management will soon become a reality.
Equally revolutionary is the gradual phasing out of chemotherapy, even for the treatment of metastatic disease, which is now dominated by immunotherapy, ADCs, and targeted therapies.
All of this without overlooking the by no means negligible proportion of urothelial carcinomas originating in the upper urinary tract, which often overlap with bladder tumors but are, in fact, clinically and biologically distinct.
This meeting aims to provide an opportunity for an open, multidisciplinary discussion of the developments that have emerged over the past year and their impact on the clinical management of genitourinary tract cancers, thanks to the presence of leading experts in the field.